SLC43A2

Across TCGA pan-cancer cohorts, SLC43A2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SLC43A2 data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SLC43A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC43A2 expression acts as an unfavorable survival marker.

STAD, SKCM, and KIRP are the cancer types where SLC43A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.096	0.667	<.001	12	view →
SKCM	OS	Median	IV	0.415	0.861	.014	9	view →
KIRP	DFS	Median	All	0.133	0.605	.014	6	view →
CESC	OS	Median	II,III,IV	0.503	0.833	.035	6	view →
LUAD	OS	Median	All	0.323	0.834	.003	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SLC43A2–STAD (OS)

Open the STAD breakdown →